ROCKET-AF: Stroke Prevention and Beyond! (8 Dec 2010)
Manesh R. Patel, MDThe ROCKET-AF trial, which was recently presented at AHA, showed that the experimental factor Xa inhibitor rivaroxaban was as effective as warfarin in preventing stroke in 14,264 AF patients and did not increase their risk of bleeding. CardioExchange welcomes one of the trial’s investigators, Manesh Patel of the Duke Clinical Research Institute, to answer our…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.